Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$32.2 million.

  • Fate Therapeutics' Consolidated Net Income rose 3291.47% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.0 million, marking a year-over-year increase of 936.93%. This contributed to the annual value of -$193.0 million for FY2024, which is 1134.46% down from last year.
  • According to the latest figures from Q3 2025, Fate Therapeutics' Consolidated Net Income is -$32.2 million, which was up 3291.47% from -$34.0 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Consolidated Net Income ranged from a high of -$24.9 million in Q1 2023 and a low of -$84.6 million during Q3 2022
  • Moreover, its 5-year median value for Consolidated Net Income was -$46.9 million (2024), whereas its average is -$52.0 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 10901.28% in 2021, then surged by 6637.63% in 2023.
  • Quarter analysis of 5 years shows Fate Therapeutics' Consolidated Net Income stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then grew by 29.05% to -$43.7 million in 2023, then plummeted by 32.55% to -$57.9 million in 2024, then skyrocketed by 44.43% to -$32.2 million in 2025.
  • Its Consolidated Net Income stands at -$32.2 million for Q3 2025, versus -$34.0 million for Q2 2025 and -$37.9 million for Q1 2025.